{"nctId":"NCT02320721","briefTitle":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","startDateStruct":{"date":"2015-01"},"conditions":["Type 2 Diabetes Mellitus"],"count":1014,"armGroups":[{"label":"HOE901-U300","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Glargine (HOE901 - U300)","Drug: Background therapy"]},{"label":"Lantus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Glargine (HOE901 - U100)","Drug: Background therapy"]}],"interventions":[{"name":"Insulin Glargine (HOE901 - U300)","otherNames":["Toujeo®"]},{"name":"Insulin Glargine (HOE901 - U100)","otherNames":["Lantus®"]},{"name":"Background therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants ≥65 years old with type 2 diabetes mellitus, inadequately controlled on antidiabetic regimens either including no insulin, or with basal insulin as their only insulin.\n* Signed informed consent.\n\nExclusion criteria:\n\n* HbA1c at screening visit:\n\n  * \\<7.0% or \\>10.0% for participants taking basal insulin.\n  * \\<7.5% or \\>11.0% for insulin-naïve participants.\n* History of type 2 diabetes mellitus for less than 1 year before screening.\n* Participants not on stable basal insulin dose (±10% in the last 8 weeks prior to screening visit).\n* Change in dose of antidiabetic treatment or initiation of new glucose-lowering medications in the last 8 weeks prior to screening.\n* Chronic (\\>10 days continuous use in previous 6 months) use of bolus insulin injections, whether given separately or as part of a combination with basal insulin, e.g. premix insulin; For insulin-naïve individuals: current or previous insulin use except for a maximum of 10 consecutive days (e.g. acute illness, surgery) during the last year prior to screening.\n* Cognitive disorder and dementia assessed clinically and by Mini-Mental State Examination (MMSE) score \\<24, or any neurologic disorder that would likely affect the participant's ability to follow the study procedure. The participant would be eligible despite an MMSE score \\<24 if the investigator determined that the low score reflected educational or cultural background and not dementia as long as the participant was otherwise able to meet the study requirements.\n* Participants who had end-stage renal disease (\\<15 mL/min/1.73m\\^2, per estimated Glomerular filtration rate (eGFR) measurement by Modification of Diet in Renal Disease (MDRD).\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26","description":"Adjusted least square (LS) means were obtained from analysis of covariance (ANCOVA) after multiple imputation of missing data including post baseline HbA1c data during the 26-week randomized period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"0.038"},{"groupId":"OG001","value":"-0.91","spread":"0.042"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period","description":"Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null},{"groupId":"OG001","value":"47.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period","description":"Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period","description":"Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period","description":"Participants without any available HbA1c assessment at Week 26 were considered as non-responders in the analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"35.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period","description":"Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"Adjusted LS means from multiple imputation approach including post baseline values during the 26-week randomized period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.122"},{"groupId":"OG001","value":"-1.77","spread":"0.135"}]}]}]},{"type":"SECONDARY","title":"Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26","description":"WHO-5 well-being index evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions, each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score was transformed into a percentage score ranging from 0 (worst possible quality of life) to 100 (best possible quality of life).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"0.751"},{"groupId":"OG001","value":"0.22","spread":"0.758"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment","description":"Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 14) values were used to determine the requirement of rescue medication. Threshold values at Week 14: FPG \\>200 mg/dL (11 mmol/L), or HbA1c \\>8.5%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment","description":"Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \\[70 mg/dL\\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"60.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"60.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"59.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment","description":"Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \\[70 mg/dL\\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.06","spread":null},{"groupId":"OG001","value":"7.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"2.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":null},{"groupId":"OG001","value":"6.36","spread":null}]}]}]},{"type":"POST_HOC","title":"Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year: By Age Categorical Data During the 26 Weeks of Treatment","description":"Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \\[70 mg/dL\\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.44","spread":null},{"groupId":"OG001","value":"7.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.01","spread":null},{"groupId":"OG001","value":"7.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null},{"groupId":"OG001","value":"2.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":null},{"groupId":"OG001","value":"2.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","spread":null},{"groupId":"OG001","value":"6.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.46","spread":null},{"groupId":"OG001","value":"6.28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":508},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}}